Omeros (OMER) Total Current Liabilities (2010 - 2026)
Omeros' (OMER) quarterly Total Current Liabilities came in at $59.4 million in Q1 2026, down 28.57% year-on-year from $83.2 million in Q1 2025, and down 23.85% quarter-over-quarter from $78.1 million in Q4 2025.
Omeros (OMER) Total Current Liabilities (2010 - 2026) Analysis & Trends
Omeros has disclosed Total Current Liabilities across 17 years of filings, most recently posting $59.4 million for Q1 2026.
- Total Current Liabilities for Q1 2026 came in at $59.4 million, down 28.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $59.4 million (down 28.57% YoY), and the FY2025 annual result was $78.1 million, down 1.84% from the prior year.
- Total Current Liabilities came in at $59.4 million for Q1 2026 at Omeros, down from $78.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $147.2 million in Q3 2023 to a low of $35.1 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $78.1 million (2025), against an average of $80.8 million.
- Across the five-year window, Total Current Liabilities jumped 296.94% in 2023 and slumped 62.21% in 2024, its largest moves.
- Omeros' Total Current Liabilities stood at $136.4 million in 2022, then tumbled by 60.91% to $53.3 million in 2023, then soared by 49.16% to $79.5 million in 2024, then retreated by 1.84% to $78.1 million in 2025, then declined by 23.85% to $59.4 million in 2026.
- The last three Total Current Liabilities figures came in at $59.4 million (Q1 2026), $78.1 million (Q4 2025), and $80.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 13.42 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 72.86 Mn |
| 10 | Omeros | 737.87 Mn | 602.55 Mn | 9.31 Mn | 59.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.44 Mn |
| Dec 31, 2025 | 78.06 Mn |
| Sep 30, 2025 | 80.76 Mn |
| Jun 30, 2025 | 85.50 Mn |
| Mar 31, 2025 | 83.22 Mn |
| Dec 31, 2024 | 79.53 Mn |
| Sep 30, 2024 | 55.62 Mn |
| Jun 30, 2024 | 59.48 Mn |
| Mar 31, 2024 | 59.06 Mn |
| Dec 31, 2023 | 53.32 Mn |
| Sep 30, 2023 | 147.18 Mn |
| Jun 30, 2023 | 143.54 Mn |
| Mar 31, 2023 | 139.19 Mn |
| Dec 31, 2022 | 136.38 Mn |
| Sep 30, 2022 | 39.51 Mn |
| Jun 30, 2022 | 38.50 Mn |
| Mar 31, 2022 | 35.07 Mn |
| Dec 31, 2021 | 51.79 Mn |
| Sep 30, 2021 | 42.82 Mn |
| Jun 30, 2021 | 47.70 Mn |